Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD’s new cancer treatment significantly improves overall survival

MSD’s new cancer treatment significantly improves overall survival

22nd December 2015

Merck Sharp & Dohme (MSD) have shown that its new treatment, Keytruda, significantly improves overall survival compared to chemotherapy in people with lung cancer and PD-L1 expression.

The study was the first of its kind to evaluate the potential of an immunotherapy compared to chemotherapy in this way. It is based on the prospective measurement of PD-L1 expression in patients with advanced non-small cell lung cancer (NSCLC), whose tumours express the PD-L1 gene. In the Phase III trial, Keytruda improved overall survival compared to chemotherapy with docetaxel. 

MSD plans to submit a supplemental biologics licence application for Keytruda to the FDA by the end of 2015. The company also plans to submit a marketing authorisation application to the European Medicines Agency in early 2016.ADNFCR-8000103-ID-801808709-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.